{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-390951","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2026-09-14T23:12:37+00:00","discovered_at":"2026-09-15T10:05:00.866902+00:00","generated_at":"2026-09-15T10:05:12.737298+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Tyra Biosciences prices $400M offering of common stock and pre-funded warrants","bullets":["9,079,000 shares priced at $22.03; pre-funded warrants for 9,078,529 shares at $22.029.","Gross proceeds expected ~$400.0M; closing expected September 15, 2026.","Net proceeds to advance dabogratinib in LG-UTUC, IR NMIBC, and achondroplasia programs.","Offering led by RA Capital; Jefferies, Guggenheim, Cantor, Barclays, William Blair as book-runners.","Warrants exercisable at $0.001; beneficial ownership limits selectable up to 19.99%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-390951","json":"https://secwatch.observer/filing/0001193125-26-390951.json","markdown":"https://secwatch.observer/filing/0001193125-26-390951.md","text":"https://secwatch.observer/filing/0001193125-26-390951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526390951/0001193125-26-390951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526390951/d102025d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-15T10:05:12.737298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}